強気
$8.47
シナリオ価格
$2.530
-0.049 (-1.94%)終値時点
SS Innovations International, Inc. is a developer of surgical robotic technologies. The Company’s product range includes its proprietary SSi Mantra surgical robotic system and its comprehensive suite of SSi Mudra surgical instruments, which support a variety of surgical procedures including robotic cardiac surgery. The SSi Mantra Surgical Robotic System is designed to enable surgeons to perform a wide range of surgical procedures including cardiovascular, thoracic, head and neck, gynecological, urological, cancer and general surgeries. The SSi Mantra 3 is comprised of components, such as Surgeon Console, Patient-Side Robotic Arm Carts, and Vision Cart. Its instruments under development include NADI-Automated Coronary Anastomotic Connector, SSi Multi-Fire Clip Applier, SSi Ultrasonic Surgical Device, SSi Maya-XR Pre-Operative Simulator, SSi Holographic Anatomy, SSi Yog-Tele Proctor, SSi Chitrasa-Advanced DICOM Viewer and SSi Mixed Reality Headset.
Currently, SS Innovations International Inc (SSII) is not a good buy. The stock is trading at $2.53, which is significantly below its analyst price target of $7, indicating potential upside. However, the stock has shown a year-to-date change of -55.22% and a one-year change of -74.65%, reflecting substantial losses. Additionally, the RSI is at 31.583, suggesting the stock is oversold but also indicating a lack of momentum for recovery. The main risk is the company's negative net income, which was -2,661,350 USD in Q2 2026, highlighting ongoing financial struggles.
シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

SS Innovations Responds to FDA Information Request for SSi Mantra

SS Innovations Advances Global Expansion and Surgical Milestones

SS Innovations Showcases SSi Mantra Surgical Robot at SRS 2026

SS Innovations Appoints New CFO Sarah Romano

SS Innovations Appoints New CFO to Drive Growth
SS Innovations International, Inc. is a developer of surgical robotic technologies. The Company’s product range includes its proprietary SSi Mantra surgical robotic system and its comprehensive suite of SSi Mudra surgical instruments, which support a variety of surgical procedures including robotic cardiac surgery. The SSi Mantra Surgical Robotic System is designed to enable surgeons to perform a wide range of surgical procedures including cardiovascular, thoracic, head and neck, gynecological, urological, cancer and general surgeries. The SSi Mantra 3 is comprised of components, such as Surgeon Console, Patient-Side Robotic Arm Carts, and Vision Cart. Its instruments under development include NADI-Automated Coronary Anastomotic Connector, SSi Multi-Fire Clip Applier, SSi Ultrasonic Surgical Device, SSi Maya-XR Pre-Operative Simulator, SSi Holographic Anatomy, SSi Yog-Tele Proctor, SSi Chitrasa-Advanced DICOM Viewer and SSi Mixed Reality Headset. It operates in the Healthcare sector.
Currently, SS Innovations International Inc (SSII) is not a good buy. The stock is trading at $2.53, which is significantly below its analyst price target of $7, indicating potential upside. However, the stock has shown a year-to-date change of -55.22% and a one-year change of -74.65%, reflecting substantial losses. Additionally, the RSI is at 31.583, suggesting the stock is oversold but also indicating a lack of momentum for recovery. The main risk is the company's negative net income, which was -2,661,350 USD in Q2 2026, highlighting ongoing financial struggles.
投稿はまだありません
登録またはログインして議論に参加本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。